Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
No results matched your search
UCB SA ADR (UCBJY)
OTC Markets
| Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| UCBJY | OTC Markets | USD | Delayed | |
| UCBb | BATS Europe | EUR | Delayed | |
| 0NZT | London | EUR | Real-time | |
| UCB | Frankfurt | EUR | Delayed | |
| UCB | TradeGate | EUR | Delayed | |
| UCB | Brussels | EUR | Real-time |
Add to/Remove from a Portfolio
Add to Portfolio
47.48
+0.04
+0.08%
- Volume: 13,290
- Bid/Ask: 0.00 / 0.00
- Day's Range: 45.85 - 47.54
UCB ADR
47.48
+0.04
+0.08%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Overview
- Profile
- Historical Data
- Index Component
Prev. Close47.44
Day's Range45.85 - 47.54
RevenueN/A
Open46.52
52 wk Range32.45 - 68
EPSN/A
Volume13,290
Market Cap17.47B
Dividend (Yield)0.67 (1.14%)
Average Volume (3m)17,280
P/E RatioN/A
BetaN/A
1-Year Change - 5.64%
Shares OutstandingN/A
Next Earnings DateApr 28, 2021
What is your sentiment on UCB ADR?
Members' Sentiments:
or
Market is currently closed. Voting is open during market hours.
UCB SA ADR News
UCB SA reports FY results
By Seeking Alpha - Feb 25, 2021
UCB SA (UCBJF): FY Non-GAAP EPS of€5.36; GAAP EPS of€3.87.Revenue of€5.35B (+9.0% Y/Y).Press Release
UCB SA ADR Analysis
UCB SA 2020 Q4 - Results - Earnings Call Presentation
By Seeking Alpha - Feb 25, 2021
Technical Summary
| Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Neutral | Sell | Strong Sell | Neutral |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Buy | Buy | Strong Sell | Strong Sell | Sell |
Filter Table By:
| Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
|---|---|---|---|---|---|
| Emerging Patterns | |||||
| Bullish Engulfing | 5H | Current | |||
| Thrusting Bearish | 1D | Current | |||
| Engulfing Bearish | 1W | Current | |||
| Falling Three Methods | 1M | Current | |||
| Completed Patterns | |||||
| Bullish doji Star | 1W | 1 | Feb 21, 2021 | ||
| Engulfing Bearish | 1W | 5 | Jan 24, 2021 | ||
| Bullish Engulfing | 1H | 7 | Mar 04, 2021 20:00 | ||
UCB SA ADR Quotes
| Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| OTC Markets | 47.48 | 0.00 | 0.00 | 13,290 | +0.08% | USD | 05/03 | ||
| BATS Europe | 79.47 | 0.00 | 0.00 | 52,487 | -2.27% | EUR | 05/03 | ||
| London | 77.84 | 0.00 | 0.00 | 33,378 | -3.56% | EUR | 05/03 | ||
| Frankfurt | 79.64 | 0.00 | 0.00 | 0 | -0.87% | EUR | 05/03 | ||
| TradeGate | 78.06 | 78.60 | 78.82 | 315 | -1.91% | EUR | 05/03 | ||
| Brussels | 77.54 | 0.00 | 0.00 | 472,358 | -3.68% | EUR | 05/03 |
Trending Stocks
| Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| FBN Holdings | 7.10 | 7.10 | 6.85 | +0.05 | +0.71% | 26.50M | 05/03 | ||
| MTN Nigeria | 160.20 | 160.20 | 160.20 | -9.80 | -5.76% | 643.20K | 05/03 | ||
| Guaranty Trust Bank | 31.20 | 31.05 | 30.90 | -0.50 | -1.59% | 20.83M | 05/03 | ||
| Zenith Bank | 25.30 | 25.40 | 24.95 | 0.00 | 0.00% | 46.85M | 05/03 | ||
| UBA | 7.95 | 7.95 | 7.85 | 0.00 | 0.00% | 23.30M | 05/03 | ||
| Access Bank | 7.90 | 7.85 | 7.70 | +0.10 | +1.28% | 10.47M | 05/03 | ||
| Dangote Sugar | 16.90 | 16.90 | 16.40 | +0.40 | +2.42% | 1.98M | 05/03 | ||
| Lafarge Africa | 22.20 | 22.20 | 21.80 | +2.00 | +9.90% | 1.65M | 05/03 | ||
| STANBIC IBTC Bank | 44.00 | 44.00 | 44.00 | +4.00 | +10.00% | 82.37K | 05/03 | ||
| Oando Plc | 2.65 | 3.00 | 2.65 | -0.25 | -8.62% | 4.05M | 05/03 |
UCB SA ADR Company Profile
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Read More
Write your thoughts about UCB SA ADR
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.